Venous Thromboembolic Risk of Estradiol Valerate–Dienogest Compared with Ethinyl Estradiol–Levonorgestrel Combined Oral Contraceptives
Authors:
Open Access
- 16 January 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 143 (3) , 431-434
Abstract
This pooled analysis compared the risk of venous thromboembolism (VTE) associated with combined oral contraceptives (COCs) containing estradiol (E2) valerate–dienogest with those containing ethinyl E2–levonorgestrel. Data were retrieved from two large, prospective, observational cohort studies. Propensity score subclassification was applied to balance baseline parameters between the COC user cohorts. Crude and adjusted hazard ratios (HRs) were calculated based on the extended Cox model. The pooled data set included 11,616 E2 valerate–dienogest users and 18,681 ethinyl E2–levonorgestrel users, contributing 17,932 and 29,140 women-years of observation, respectively. A significantly decreased VTE risk in E2 valerate–dienogest COCs compared with ethinyl E2–levonorgestrel COCs was observed (propensity score–stratified HR 0.46, 95% CI, 0.22–0.98). This pooled analysis expands data from a previous postauthorization safety study and provides valuable real-world safety information on the relative safety of current COCs.Keywords
This publication has 9 references indexed in Scilit:
- Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapiesJournal of Endometriosis and Pelvic Pain Disorders, 2021
- Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE studyFrontiers in Women’s Health, 2020
- Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE studyThe European Journal of Contraception & Reproductive Health Care, 2019
- Combined hormonal contraception and the risk of venous thromboembolism: a guidelineFertility and Sterility, 2017
- Impact of estrogen type on cardiovascular safety of combined oral contraceptivesContraception, 2016
- Efficacy and Safety of a Combined Oral Contraceptive Containing Estradiol Valerate/Dienogest: Results from a Clinical Study Conducted in North AmericaJournal of Women's Health, 2014
- An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogestGynecological Endocrinology, 2011
- A Strengthening Programme for Weak AssociationsInternational Journal of Epidemiology, 1988
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983